Lupus Nephritis Save
Sponsored by:
Speaker bios:
Dr. Michelle Petri
Michelle Petri, M.D. M.P.H. is a Professor of Medicine at the Johns Hopkins University School of Medicine. She attended medical school at Harvard University and fulfilled her internal medicine residency at the Massachusetts General Hospital. In addition, she completed two fellowship programs at the University of California, San Francisco in allergy and immunology and rheumatology. Dr. Petri is the Director of the Hopkins Lupus Cohort, a longitudinal study of morbidity and mortality in systemic lupus erythematosus, and Co-Director of the Hopkins Lupus Pregnancy Center. She is a Master of the American College of Rheumatology.
Dr. Hans-Joachim Anders
Hans-Joachim Anders received his clinical training at the University of Munich and became a board-certified internist, nephrologist, rheumatologist, and immunologist. He directs the Division of Nephrology at the Inner City Campus of the University of Munich (LMU). As a professor of nephrology at the University of Munich, he teaches all aspects of clinical nephrology and coordinates a Medical Faculty program and an Else-Kröner-Fresenius Graduate School (FöFoLe Inflammation) that together fund 1 year of full time basic research for 50-55 medical students each year. His own research lab focusses on immune mechanisms of kidney injury and repair as well as preclinical drug testing for chronic kidney disease. He has published more than 460 original articles and reviews and received several national and international awards. Thompson Reuters lists him as a Highly-Cited Researcher and expertscape.com top-lists him for the topics lupus nephritis and glomerulonephritis. He is the current Editor-in-Chief of Nephrol Dial Transplantation, the lead journal of the European Renal Association and its 26.000 members from all over the world.
Dr. Nathalie Costedoat-Chalumeau
Nathalie Costedoat-Chalumeau MD, PhD, is currently Professor of Medicine at Paris University and Senior Hospital practitioner at the Reference Center for Systemic and Autoimmune Diseases, Department of Medicine, Cochin Hospital and, one of the five French national reference in France for rare autoimmune and systemic diseases. She trained in Internal Medicine, Immunology, Pharmacology and Rheumatology at the Pitié-Salpêtrière and Cochin Hospitals in Paris; she joined the Cochin Hospital soon after completing her training, and in 2010 she became a Full Professor.
Natalie’s research and practice has focused on lupus and the antiphospholipid syndrome and has been involved on studies leading to landmark publications in hydroxychloroquine and its measurement in blood, adherence to treatment, and pregnancy in women with SLE and APS. She designed and successfully led several national and international longitudinal and cohort studies on SLE and APS: the PLUS study, the Adherence study, the GR2 study, and the neonatal lupus cohort (in collaboration with Dr. Jill Buyon, another SLICC member). She brings this extensive experience to the SLICC group. Dr. Costedoat-Chalameau has published extensively including original papers in international journals; she is also a reviewer for national and international journal, and since 2013, member of the Editorial Board of Lupus Science and Medicine.
Dr. Maria Dall'Era
Maria Dall’Era is the Jean S. Engleman Distinguished Professor of Medicine and Chief of the Division of Rheumatology at the University of California, San Francisco. She is Director of the UCSF Rheumatology Clinical Research Center and Co-Director of the Lupus Center. She serves as the Co-Chair of the Lupus Therapeutics Board of Directors under the Lupus Research Alliance and is a steering committee member of the Lupus Academy, the Lupus Forum, and the Lupus 21st Century annual conference. She is the PI of a CDC-funded population- based longitudinal lupus cohort in the San Francisco Bay Area called the California Lupus Epidemiology Study and the PI on an NIH/ITN-sponsored trial of a novel agent for lupus nephritis. She is also a member of the core leadership team developing the American College of Rheumatology Guidelines for the Treatment of SLE and lupus nephritis.
She received her undergraduate degree in Immunology from the University of California, Berkeley, and completed her Medical Degree from the University of California, San Francisco (UCSF), where she later completed her Internship, Residency, and Chief Residency in Internal Medicine. She completed her Fellowship in Rheumatology at UCSF. She has authored numerous publications in the areas of SLE and lupus nephritis. She is a co-author of the Treatment of Lupus Nephritis chapter in Up-To-Date. She received the Edmund L. Dubois Memorial Lectureship Award from the American College of Rheumatology and the Evelyn V. Hess award from the Lupus Foundation of America.
Dr. Brad Rovin
Dr. Brad H. Rovin is the Lee A. Hebert Professor of Nephrology. Dr. Rovin received his Bachelor of Science in Chemical Engineering from Northwestern University in Evanston Illinois and his Doctor of Medicine from the University of Illinois Medical School in Chicago, Illinois. He completed a residency in Internal Medicine at Barnes Hospital in St. Louis Missouri, and a Fellowship in Nephrology at Washington University School of Medicine, St. Louis. He joined the Ohio State University College of Medicine Faculty in 1990, became Director of the Division of Nephrology in 2004, and served as Vice Chairman of Medicine for Research from 2009- 2019. In 2019 he became the Medical Director of the Ohio State University Center for Clinical Research Management.
Dr. Rovin has had several committee and leadership roles in the American Society of Nephrology, including the annual meeting program committee, running the Glomerular Diseases Pre-Course and Co-Editing NephSAP-Glomerular Diseases, a continuing education program of the Society. He serves as deputy Editor of Kidney International, the flagship journal of the International Society of Nephrology, and he is Co-Chair for glomerular disease guideline development for the Kidney Disease Improving Global Outcomes effort. Most recently he received the Evelyn Hess Award from the Lupus Foundation of America for research contributions to improve the understanding of lupus nephritis.
Dr. Rovin’s laboratory studies the immunopathogenesis of glomerular and autoimmune diseases and focuses on biomarker development for non-invasive assessment of kidney pathology. He is heavily involved in clinical trial development and design for investigator-initiated and industry-sponsored trials. He is a founding member of NephroNet, a grass-roots nephrology clinical trial organization, and the Lupus Nephritis Clinical Trials Network. He is and has been the Principal Investigator on several trials of novel therapeutics for glomerular diseases.
